Corcept Therapeutics Incorporated (CORT) Balance Sheet

The sequential increase in equity from $638.0M to $705.8M is the largest quarterly jump in the observed period, outpacing the prior year's growth rate. This suggests that the company's reinvestment strategy is yielding tangible balance sheet expansion, likely supported by robust revenue growth and operating leverage. The consistent upward trend in retained earnings, which reached $654.6M, indicates that management is successfully converting top-line growth into shareholder value without relying on external financing.

The company's debt levels are immaterial relative to its equity base, with total debt representing just 1.3% of total assets. This near-zero leverage suggests that Corcept is not reliant on debt financing to fund its operations or growth initiatives, which is consistent with its asset-light, high-margin business model. The absence of significant debt also mitigates refinancing risk and interest rate sensitivity, allowing management to allocate cash flows toward R&D and legal defense without the burden of fixed obligations.

The composition of assets is heavily weighted toward current assets and cash, with property, plant, and equipment representing a mere 1.4% of total assets. The absence of goodwill indicates that the company has not engaged in significant acquisitions, relying instead on organic growth and internal pipeline development. This asset-light structure implies that the balance sheet is not burdened by depreciation or impairment risks, but it also means that the company's value is concentrated in its intellectual property and commercial infrastructure, which are not reflected on the balance sheet.

The overwhelming majority of equity is derived from retained earnings, which have grown consistently over the past ten quarters from $430.3M to $654.6M. This suggests that the company is not relying on external capital injections or excessive stock-based compensation to bolster its equity base. However, the prior cash flow analysis noted that SBC averaged $15.9M per quarter, which, while non-cash, does dilute existing shareholders over time. Investors should monitor whether the pace of buybacks, which totaled $199.3M over the last four quarters, adequately offsets this dilution.

The current ratio has remained above 2.8 for the past five quarters, indicating that current assets comfortably cover current liabilities. Cash levels, while down from the $120.5M peak in 2025Q4, are still substantial relative to the company's operating expenses, which are primarily R&D and SG&A. Given the company's minimal debt and strong cash generation, the liquidity position appears more than adequate to fund ongoing clinical trials and legal defense. The slight decline in cash may reflect increased investment in working capital or share repurchases, but the overall buffer remains healthy.